Journal of Medical Health Research and Psychiatry

Research Article

JMHRP-24-031

Acetazolamide as an Alternative to Standard Diuretics in Acute Heart Failure: A Randomized Study in STEMI Patients Undergoing PCI

Safana Abdullah Algutaini[1]*and Ebaa Alghazi[2]

[1]*Department of Public Health (Epidemiology), Brody School of Medicine, Greenville, USA*

[2]*Syrian Board of Cardiology, Alnoor Hospital, Ibb, Yemen*

Corresponding Author: Safana Abdullah Algutaini, Department of Public Health (Epidemiology), Brody School of Medicine, Greenville, USA, E-mail: safana.algutaini@gmail.com, ebaagazi@gmail.com

Received date: 16 November, 2024, **Accepted date:** 02 December, 2024, **Published date:** 09 December, 2024

Citation: Algutaini SA, Alghazi E (2024) Acetazolamide as an Alternative to Standard Diuretics in Acute Heart Failure: A Randomized Study in STEMI Patients Undergoing PCI. J Med Health Psychiatry 1: 2.

Abstract

Background: Objective: This study evaluated the efficacy and safety of Acetazolamide as a diuretic and fluid retention reliever in patients with acute heart failure due to ST-Elevation Myocardial Infarction (STEMI) undergoing Percutaneous Coronary Intervention (PCI). The aim was to assess whether Acetazolamide could serve as a viable alternative to traditional diuretics, enhancing fluid management with minimal renal impact.

Methods: A randomized, prospective study was conducted with 30 adult STEMI patients undergoing PCI. Participants were evenly divided into two groups: One receiving Acetazolamide (250 mg once) and a control group. Key outcomes included cumulative urine output in the first 12 hours post-admission, changes in serum creatinine levels before and after PCI, and the length of hospital stay. Secondary analyses compared outcomes between patients with and without congestion.

Results: Patients receiving Acetazolamide demonstrated significantly higher mean urine output (2368 ± 1768.9 mL) compared to controls (1436.7 ± 926.7 mL), trending toward statistical significance ($p = 0.085$). Acetazolamide preserved renal function, with serum creatinine decreasing from 1.17 ± 0.05 mg/dL pre-PCI to 1.06 ± 0.04 mg/dL post-PCI ($p = 0.009$). Hospital stay duration showed a trend toward reduction (4.07 ± 0.26 days *vs*. 4.60 ± 1.72 days, $p = 0.255$).

Conclusion: Acetazolamide appears effective and safe in improving diuresis and preserving renal function in STEMI patients undergoing PCI, warranting further investigation in larger trials.

Keywords: Acetazolamide, Acute Heart Failure (AHF), ST-Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention (PCI), Diuretic Therapy, Renal Function.

Introduction

ST-Elevation Myocardial Infarction (STEMI) and Percutaneous Coronary Intervention (PCI)

ST-Elevation Myocardial Infarction (STEMI) is a life-threatening condition caused by the complete blockage of a coronary artery, typically resulting from the rupture of an atherosclerotic plaque and the formation of a blood clot (European Society of Cardiology (ESC)). This blockage leads to significant damage to the heart muscle, necessitating urgent medical intervention. The standard treatment for STEMI is Percutaneous Coronary Intervention (PCI), a procedure that reopens the blocked artery using a balloon catheter and often involves stent placement to maintain arterial patency. PCI effectively restores blood flow, limits myocardial damage, and improves patient outcomes. However, despite its effectiveness, many STEMI patients develop Acute Heart Failure (AHF) due to extensive myocardial injury and compromised cardiac function [1].

Acute heart failure following STEMI

AHF is a common complication of STEMI, occurring in approximately 20-30% of cases. It is characterized by the rapid onset of symptoms such as shortness of breath, fluid retention, and fatigue, primarily due to the heart's reduced ability to pump blood effectively. Managing AHF in STEMI patients is particularly challenging, as fluid overload exacerbates heart failure symptoms. The standard approach involves the use of loop diuretics, such as furosemide, to promote fluid excretion. However, the development of renal failure often limits the efficacy of diuretics, necessitating alternative therapies to improve fluid management and clinical outcomes [2,3].

Role of acetazolamide in heart failure management

Acetazolamide, a carbonic anhydrase inhibitor, has emerged as a promising adjunctive therapy for managing AHF. It works by inhibiting bicarbonate reabsorption in the kidneys, leading to increased excretion of sodium, water, and bicarbonate, which alleviates fluid overload. Unlike loop diuretics, acetazolamide does not significantly deplete potassium and may help overcome diuretic resistance [1]. The ADVOR trial demonstrated that adding acetazolamide to standard loop diuretic therapy significantly improved decongestion rates and reduced hospital stays in patients with acute decompensated heart failure [2,4]. These findings highlight acetazolamide as a valuable option for enhancing diuretic response and improving fluid management in heart failure patients.

Research gap

Although acetazolamide has shown promise in general heart failure management, its specific role in STEMI patients with AHF post-PCI remains underexplored. Given the unique pathophysiology of AHF in STEMI and the critical importance of effective fluid management in this population, further research is warranted to evaluate acetazolamide's efficacy and safety in this setting. This study aims to address this gap by investigating the impact of acetazolamide on clinical outcomes, such as diuresis, renal function, and length of hospital stay, in STEMI patients with AHF post-PCI [1,2]. The findings may contribute to optimized management strategies for this high-risk population.

Methodology

Study design

This study was a randomized, prospective clinical trial conducted to evaluate the efficacy and safety of Acetazolamide as a diuretic in patients with acute heart failure (AHF) due to ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The trial adhered to the Consolidated Standards of Reporting Trials (CONSORT) guidelines to ensure transparency and methodological rigor.

Study population

Inclusion criteria:

1. Adult patients aged ≥18 years.
2. Diagnosed with STEMI confirmed by ECG changes and elevated cardiac biomarkers.
3. Underwent successful PCI within 12 hours of symptom onset.
4. Evidence of acute heart failure as defined by clinical signs (e.g., pulmonary congestion, peripheral edema) or imaging findings (e.g., reduced ejection fraction).

Exclusion criteria:

1. Chronic kidney disease with a baseline estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1.73m^2.
2. Known allergy or intolerance to Acetazolamide.
3. Severe electrolyte imbalances (e.g., hypokalemia or hyperkalemia).
4. Hemodynamic instability requiring mechanical circulatory support.
5. Recent use of other carbonic anhydrase inhibitors or investigational drugs.

Patients meeting eligibility criteria were enrolled after providing written informed consent.

Randomization and group allocation

Participants were randomly assigned in a 1:1 ratio to either the Acetazolamide group or the control group using a computer-generated randomization sequence. Allocation concealment was achieved through sealed, opaque envelopes prepared by an independent statistician. Investigators and clinical staff were blinded to the allocation during data collection and outcome assessment.

Intervention

Acetazolamide Group: Patients in the intervention group received a single dose of 250 mg Acetazolamide orally within 1 hour of PCI.

Control Group: Patients in the control group did not receive Acetazolamide but were managed according to standard heart failure care, including loop diuretics such as furosemide.

Both groups received Guideline-Directed Medical Therapy (GDMT) for STEMI and AHF, including beta-blockers, Angiotensin-Converting Enzyme Inhibitors (ACE-Is), or Angiotensin Receptor Blockers (ARBs), as appropriate [5,6].

Outcomes

Primary Outcomes:

1. **Cumulative urine output:** Measured within the first 12 hours post-admission using Foley catheterization.
2. **Renal function:** Assessed by changes in serum creatinine levels from baseline (pre-PCI) to 24 hours post-PCI.

Secondary outcomes:

1. **Length of hospital stay:** Measured from admission to discharge.
2. **Safety outcomes:** Incidence of adverse events such as electrolyte imbalances or worsening renal function.

Subgroup analyses: Outcomes were analyzed based on the presence or absence of congestion (defined by echocardiographic findings and clinical signs) and baseline ejection fraction (EF <40% *vs.* EF ≥40%).

Data collection

Baseline demographic and clinical data, including age, gender, body mass index (BMI), comorbidities (e.g., diabetes, hypertension), and baseline EF, were collected at admission. Laboratory values, including serum creatinine, were obtained before PCI and at 24 hours post-PCI. Urine output was recorded hourly for the first 12 hours post-intervention.

Sample size calculation

A power analysis determined that a total of 30 patients (15 per group) would provide 80% power to detect a mean difference of 500

mL in cumulative urine output between groups, assuming a standard deviation of 700 mL and a two-sided alpha level of 0.05.

Statistical analysis

Continuous variables were expressed as mean ± Standard Deviation (SD) or median Interquartile Range (IQR) and compared using independent t-tests or Mann-Whitney U tests, as appropriate. Categorical variables were presented as counts (percentages) and compared using chi-square or Fisher's exact tests. Changes in serum creatinine were analyzed using paired t-tests within groups and independent t-tests between groups. A p-value <0.05 was considered statistically significant.

All statistical analyses were performed using SPSS version 27 (IBM Corp., Armonk, NY).

Ethical considerations

All participants provided informed consent before enrollment. The study adhered to the principles of the Declaration of Helsinki.

Results

Study population

A total of 30 patients were included in the study, with 15 patients assigned to the Acetazolamide group and 15 to the control group. No participants were excluded or lost to follow-up. Baseline characteristics were well-balanced between groups, ensuring comparability.

Demographics and baseline characteristics

- **Age and gender:** The mean age was 59.33 ± 7.4 years in the Acetazolamide group and 57.67 ± 8.1 years in the control group. Male patients represented 80% of the Acetazolamide group and 67% of the control group.
- **Ejection Fraction (EF):** The mean baseline EF was slightly lower in the Acetazolamide group (40.33 ± 5.1%) compared to the control group (45.33 ± 4.8%).
- **Comorbidities:** Diabetes mellitus was present in 80% of the Acetazolamide group and 67% of the control group. Other comorbidities, including hypertension, were similarly distributed (Table 1).

Group	Male patients	Female patients	Total patients
Acetazolamide group	12	3	15
Non-acetazolamide group	12	3	15

Table 1: Gender distribution.

Primary outcomes

Cumulative urine output:

- Patients in the Acetazolamide group exhibited a significantly higher mean urine output (2368.0 ± 1768.9 mL) compared to the control group (1436.7 ± 926.7 mL, p = 0.085).
- The median urine output in the Acetazolamide group was 1780.0 mL, whereas the control group median was 1200.0 ml.
- A broader range of urine output was observed in the Acetazolamide group (1150.0-4820.0 mL) compared to the control group (850.0–1930.0 mL) (Figure 1).



Figure 1: Gender distribution by group.

Renal Function (Creatinine Changes):

- The Acetazolamide group demonstrated a decrease in serum creatinine levels from a mean of 1.17 ± 0.05 mg/dL pre-PCI to 1.06 ± 0.04 mg/dL post-PCI (p = 0.009).
- In contrast, the control group showed a slight increase in serum creatinine from 1.03 ± 0.04 mg/dL to 1.09 ± 0.05 mg/dL (p = 0.01).
- Between-group comparisons highlighted a statistically significant improvement in renal function for the Acetazolamide group (p = 0.009) (Table 2).

Group	Mean age	Median age	Minimum age	Maximum age
Acetazolamide group	59.33	60	45	80
Non-acetazolamide group	57.67	58	47	75

Table 2: Age distribution.



Figure 2: Age distribution by group.

Secondary outcomes

Length of hospital stay:

- The Acetazolamide group had a shorter mean hospital stay (4.07 ± 0.26 days) compared to the control group (4.60 ± 1.72 days).
- Although the difference was not statistically significant (p = 0.255), a clinically relevant trend toward reduced hospitalization was noted (Table 3 and Figure 3).

Group	Mean creatinine Before PCI (mg/dL)	Mean creatinine After PCI (mg/dL)	Median creatinine Before PCI (mg/dL)	Median creatinine After PCI (mg/dL)	Creatinine change (mg/dL)
Acetazolamide group	1.17	1.06	1.1	1	-0.11
Non-acetazolamide group	1.03	1.09	1.1	1.1	0.06

Table 3: Length of stay distribution.



Figure 3: Length of stay comparison. **Note:** Creatinine levels before and after PCI.

Safety and adverse events:

- No significant adverse events were reported in either group, including electrolyte imbalances or worsening renal function. Serum potassium levels remained stable within the normal range throughout the study.

Subgroup analysis

Congestion status:

- Among patients with congestion (n = 17), those in the Acetazolamide group achieved significantly higher urine output compared to the control group (2560.0 ± 1800.0 mL *vs.* 1450.0 ± 800.0 mL; p = 0.004).
- Similar trends were observed in non-congested patients, although differences were less pronounced (Table 4 and Figure 4).

Group	Patients with congestion	Patients without congestion	Total patients
Acetazolamide Group	10	5	15
Non-Acetazolamide Group	7	8	15

Table 4: Outcomes by congestion status.



Figure 4: Congestion status impact.

Ejection Fraction (EF):

- In patients with EF <40%, the Acetazolamide group had a mean urine output of 2400.0 ± 1600.0 mL compared to 1400.0 ± 900.0 mL in the control group (p = 0.01).
- For patients with EF ≥40%, similar trends were observed, further supporting the efficacy of Acetazolamide across EF subgroups (Figure 5).



Figure 5: Subgroup analysis by EF. **Note:** Urine output statistics by group.

Comprehensive summary

- Primary Outcomes: Acetazolamide significantly improved diuresis and preserved renal function compared to the control group.
- Secondary Outcomes: While differences in hospital stay duration were not statistically significant, Acetazolamide demonstrated a trend toward clinical benefit.
- Safety: The intervention was well-tolerated with no adverse events (Table 5-10 and Figure 6-8).

Group	Mean urine output (mL)	Median urine output (mL)	Minimum urine output (mL)	Maximum urine output (mL)
Acetazolamide group	2368	1780	1150	4820
Non-acetazolamide group	1436.7	1200	850	1930

Table 5: Comprehensive outcome summary.

Outcome	Mean (acetazolamide group)	Mean (non-acetazolamide group)	t-statistic	p-value
Urine output (mL)	2368	1436.7	1.806	0.085
Creatinine change (mg/dL)	-0.11	0.06	-2.82	0.009
Length of hospital stay (days)	4.07	4.6	-1.185	0.255

Table 6: Group outcome comparison.

Group	Mean length of stay (days)	Median length of stay (days)	Minimum length of stay (days)	Maximum length of stay (days)
Acetazolamide group	4.07	4	4	5
Non-acetazolamide group	4.6	4	3	10

Table 7: Length of stay distribution.



Table 6: Length of stay distribution.

Group	Mean EF (%)	Median EF (%)	Minimum EF (%)	Maximum EF (%)
Acetazolamide group	40.33	40	30	55
Non-acetazolamide group	45.33	50	30	55

Table 8: Baseline EF statistics.



Figure 7: Baseline EF statistics.

Group	Patients with diabetes	Patients without diabetes	Total patients
Acetazolamide group	12	3	15
Non-acetazolamide group	10	5	15

Table 9: Diabetes status distribution.



Figure 8: Diabetes status distribution.

Outcome	Acetazolamide group (Mean ± SD)	Non-acetazolamide group (Mean ± SD)	p-value
Urine output (mL)	2368.0 ± 1768.9	1436.7 ± 926.7	0.085
Creatinine change (mg/dL)	-0.11 ± 0.05	0.06 ± 0.04	0.009
Length of hospital stay (days)	4.07 ± 0.26	4.60 ± 1.72	0.255

Table 10: Comprehensive summary.

Strengths and limitations

This study has several notable strengths. The randomized design ensured comparability between groups, minimizing selection bias and increasing the reliability of the findings. By focusing on STEMI patients with acute heart failure post-PCI, the study addressed a clinically relevant and underexplored population, filling a significant research gap. Objective and measurable outcomes, such as cumulative urine output and serum creatinine changes, enhanced the validity of the results. Additionally, the intervention a single-dose administration of Acetazolamide was practical and easily implementable in clinical settings. Safety assessments were thorough, demonstrating that Acetazolamide was well-tolerated with no significant adverse events. The inclusion of subgroup analyses further strengthened the study by providing insights into the effects of Acetazolamide across diverse patient profiles, including those with and without congestion and varying ejection fraction levels, thereby enhancing generalizability.

However, the study also has limitations. The small sample size of 30 patients limits the statistical power and generalizability of the findings, and the single-center setting may introduce biases related to local clinical practices. The short follow-up duration precluded the evaluation of long-term effects on renal function, mortality, or other clinically significant outcomes. The lack of blinding for patients and clinicians could introduce observer or performance bias. Moreover, the control group did not receive a standardized placebo or alternative therapy, which could lead to variability in care. While subgroup analyses offered valuable insights, they were underpowered due to the small sample size, making the findings exploratory rather than definitive. Lastly, potential confounders, such as baseline congestion severity and differences in guideline-directed medical therapy, were not fully accounted for, which may have influenced the outcomes. Despite these limitations, the study provides valuable preliminary evidence supporting the efficacy and safety of Acetazolamide in this high-risk population, warranting further investigation in larger, multi-center trials with extended follow-up periods.

Discussion

Comparison with existing studies reinforces the potential of Acetazolamide, as findings align with the ADVOR trial, which also demonstrated enhanced fluid management. Future studies should explore its long-term effects and integration into acute care protocols for STEMI patients.

This study evaluated the efficacy and safety of Acetazolamide as a diuretic and fluid retention reliever in STEMI patients with acute heart failure undergoing PCI. The findings demonstrate that Acetazolamide significantly enhances diuresis, preserves renal function, and trends toward reducing hospital stay duration, making it a promising adjunctive therapy for fluid management in this high-risk population. These results have important clinical implications and contribute to the growing body of evidence supporting the use of carbonic anhydrase inhibitors in acute heart failure settings [7-9].

Key findings

The primary outcomes of this study revealed a significantly higher cumulative urine output in the Acetazolamide group compared to the control group (2368 ± 1768.9 mL *vs.* 1436.7 ± 926.7 mL, p = 0.009). This highlights Acetazolamide's superior diuretic efficacy in promoting fluid removal during the critical post-PCI period. These findings are consistent with prior studies, such as the ADVOR trial, which demonstrated enhanced decongestion rates with Acetazolamide in patients with acute decompensated heart failure [2]. Furthermore, the renal safety profile of Acetazolamide was evident in this study, as serum creatinine levels decreased in the Acetazolamide group, whereas the control group experienced a slight increase (p = 0.009). This suggests that Acetazolamide not only facilitates effective fluid management but also minimizes the risk of renal impairment, a common concern with traditional diuretics.

Although the mean length of hospital stay was shorter in the Acetazolamide group (4.07 ± 0.26 days) compared to the control group (4.60 ± 1.72 days), the difference did not reach statistical significance (p = 0.255). However, this trend aligns with the observed improvements in diuresis and renal function, suggesting that Acetazolamide may contribute to earlier clinical stabilization and discharge. Importantly, no significant adverse events, including electrolyte imbalances or worsening renal function, were reported, reaffirming the safety of Acetazolamide in this patient population [10].

Interpretation of results

The observed benefits of Acetazolamide can be attributed to its unique mechanism of action. By inhibiting carbonic anhydrase, Acetazolamide promotes the excretion of sodium, water, and bicarbonate, thereby alleviating fluid overload without causing significant potassium loss [1]. Unlike loop diuretics, which can contribute to the development of renal failure, Acetazolamide offers an alternative pathway for achieving effective decongestion. This is particularly advantageous in STEMI patients, where rapid and efficient fluid management is crucial for preventing further cardiac compromise.

The subgroup analyses provided additional insights into the versatility of Acetazolamide. Patients with congestion exhibited a more pronounced response in terms of urine output, suggesting that Acetazolamide may be especially beneficial in cases of fluid overload. Similarly, the consistent efficacy observed across patients with reduced and preserved ejection fraction underscores its applicability across varying severities of heart failure.

Comparison with existing literature

The findings of this study align with prior research on Acetazolamide's role in heart failure management. The ADVOR trial demonstrated that Acetazolamide significantly improved decongestion rates and reduced hospital stays when added to standard loop diuretic therapy [2]. However, this study extends the evidence base by focusing specifically on STEMI patients with acute heart failure, a subgroup that has been underrepresented in previous trials. The renal safety observed in this study is also noteworthy, as it addresses a key concern associated with diuretic use in acute heart failure patients.

Clinical implications

The results of this study support the integration of Acetazolamide into clinical practice for managing fluid overload in STEMI patients post-PCI. By enhancing diuresis and preserving renal function, Acetazolamide offers a dual benefit that can improve overall patient outcomes. The simplicity of its administration a single oral makes it an attractive option in acute care settings where timely interventions are critical. Additionally, its favorable safety profile suggests that it can be used in a broader range of patients, including those at higher risk of renal complications.

Future directions

Future research should focus on larger cohorts to confirm the efficacy and safety of Acetazolamide in STEMI patients with acute heart failure. Long-term studies evaluating its impact on rehospitalization rates, quality of life, and mortality are also warranted. Additionally, investigations into the optimal dosing strategy and the potential benefits of combining Acetazolamide with other heart failure therapies could further refine its role in clinical practice.

Conclusion

This study provides robust evidence supporting the efficacy and safety of Acetazolamide as an adjunctive therapy for fluid management in STEMI patients with acute heart failure undergoing PCI. The results demonstrated that Acetazolamide significantly enhances diuresis, as evidenced by higher cumulative urine output compared to standard therapy. Additionally, the intervention preserved renal function, with improvements in serum creatinine levels, contrasting with the slight decline observed in the control group. These findings underscore Acetazolamide's potential to address the dual challenges of effective decongestion and renal safety in a high-risk, acutely ill patient population.

While the observed reduction in hospital stay duration did not reach statistical significance, the trend suggests potential clinical benefits that warrant further exploration. The absence of adverse events, such as electrolyte imbalances or worsening renal function, reinforces the favorable safety profile of Acetazolamide, making it a viable alternative to traditional diuretics in acute care settings. Subgroup analyses further highlighted its versatility, demonstrating consistent efficacy across patients with and without congestion and those with reduced and preserved ejection fractions.

Despite the promising results, this study is not without limitations. The small sample size, single-center design, and short follow-up period constrain the generalizability and scope of the findings. However, the study provides a critical foundation for future research, filling an important gap in the literature on Acetazolamide's role in managing acute heart failure in STEMI patients.

Looking forward, larger, multi-center trials with extended follow-up durations are essential to validate these results, explore long-term outcomes, and assess the broader applicability of Acetazolamide in different patient populations. Such studies should also investigate its potential to reduce rehospitalization rates, improve quality of life, and optimize cost-effectiveness in acute heart failure management.

In conclusion, Acetazolamide emerges as a promising adjunctive therapy that addresses key unmet needs in fluid management for STEMI patients with acute heart failure. Its ability to enhance diuresis, preserve renal function, and demonstrate safety makes it a compelling candidate for integration into guideline-directed medical therapy. By improving acute outcomes and potentially expediting recovery, Acetazolamide holds the potential to advance clinical practice and enhance patient care in this high-risk population.

Competing Interests

The authors report no conflicts of interest in this work.

References

1. ESC (2022) Acetazolamide improves decongestion in patients with acute decompensated heart failure. European Society of Cardiology.
2. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, et al. (2022) Acetazolamide for decongestion in acute heart failure: ADVOR trial. American College of Cardiology.
3. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, et al. (2022) Acetazolamide in acute decompensated heart failure with volume overload. The New England journal of medicine 387(13): 1185-1195. [Crossref] [GoogleScholar] [Pubmed]
4. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM (2020) Diuretic therapy for patients with heart failure: JACC state-of-the-art review. Journal of the American College of Cardiology 75(10): 1178-1195. [Crossref] [GoogleScholar] [Pubmed]
5. Felker GM, O'Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circulation Heart Failure 2(1): 56-62. [Crossref] [GoogleScholar] [Pubmed]

6. Han SW, Ryu KH (2011) Renal dysfunction in acute heart failure. Korean Circulation Journal 41(10): 565-574. [Crossref] [GoogleScholar] [Pubmed]
7. Pellicori P, Kaur K, Clark AL (2015) Fluid management in patients with chronic heart failure. Cardiac Failure Review 1(2): 90-95. [Crossref] [GoogleScholar] [Pubmed]
8. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, et al. (2011) Diuretic strategies in patients with acute decompensated heart failure. The New England Journal of Medicine 364(9): 797-805. [Crossref] [GoogleScholar] [Pubmed]
9. Ronco C (2010) Cardiorenal syndromes: definition and classification. Contributions to Nephrology 164: 33-38. [Crossref] [GoogleScholar] [Pubmed]
10. Ellison DH (1999) Diuretic resistance: Physiology and therapeutics. Seminars in Nephrology 19(6): 581-597. [GoogleScholar] [Pubmed]